natgillin/translations-raw huggingface dataset:
In a double-blind study in CHB patients with YMDD mutant HBV and compensated liver disease (NUC20904), with a reduced virological and biochemical response to lamivudine (n=95), the addition of adefovir dipivoxil 10 mg once daily to ongoing lamivudine 100mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log10 copies/ml compared to a median increase of 0.3 log10 copies/ml in those patients receiving lamivudine monotherapy.
U dvostruko slijepom ispitivanju u bolesnika s kroničnim hepatitisom B s YMDD-mutiranim HBV-om i kompenziranom bolešću jetre (NUC20904), koji su imali smanjeni virološki i biokemijski odgovor na lamivudin (n=95), dodavanje adefovir dipivoksila u dozi od 10 mg jedanput na dan postojećoj dozi lamivudina od 100 mg tijekom 52 tjedna dovelo je do medijana smanjenja HBV DNK-a od 4,6 log10 kopija/ml u usporedbi s medijanom povećanja od 0,3 log10 kopija/ml u bolesnika koji su primali samo lamivudin.
In a double-blind, controlled clinical trial, 473 adults, 60 years of age or older, were randomised to receive a single dose of ZOSTAVAX either concomitantly (N=237), or nonconcomitantly with 23- valent pneumococcal polysaccharide vaccine (N=236).
U dvostruko slijepom, kontroliranom, kliničkom ispitivanju, 473 odraslih u dobi od 60 godina i starijih bilo je randomizirano u skupinu koja je primila jednokratnu dozu cjepiva ZOSTAVAX istodobno (N=237) odnosno u skupinu koja ga nije primila istodobno s 23-valentnim pneumokoknim polisaharidnim cjepivom (N=236).
In a double-blind, controlled clinical trial, 762 adults 50 years of age and older were randomised to receive a single dose of ZOSTAVAX administered either concomitantly (N=382) or nonconcomitantly (N=380) with inactivated split influenza vaccine.
U dvostruko slijepom, kontroliranom, kliničkom ispitivanju, 762 odrasle osobe u dobi od 50 godina i starijih bilo je randomizirano u skupinu koja je primila jednokratnu dozu cjepiva ZOSTAVAX istodobno (N=382) odnosno u skupinu koja ga nije primila istodobno (N=380) s inaktiviranim cjepivom protiv gripe koje sadrži samo površinske antigene virusa gripe (tzv. split cjepivo).
In a double-blind, crossover study, the reduction in glycosylated haemoglobin levels after 12 weeks dosing was 0.37 percentage points with insulin lispro, compared to 0.03 percentage points for soluble insulin (p = 0.004).
U dvostruko slijepom ukriženom ispitivanju razine glikoziliranog hemoglobina smanjene su za 0,37 postotnih bodova nakon 12 tjedana liječenja inzulinom lispro, a za 0,03 postotna boda nakon primjene topljivog inzulina (p = 0,004).
In a double-blind, placebo-controlled trial in patients with ADPKD, elevation (>3 x upper limit of normal [ULN]) of ALT was observed in 4.4% (42/958) of patients on tolvaptan and 1.0% (5/484) of patients on placebo, while elevation (>3xULN) of AST was observed in 3.1% (30/958) of patients on tolvaptan and 0.8% (4/484) patients on placebo.
U dvostruko slijepom placebom kontroliranom isipitivanju na bolesnicima s ADPBB-om zabilježeno je povišenje (>3 x gornje granice normale [GGN]) ALT-a u 4,4% (42/958) bolesnika na tolvaptanu i u 1,0% (5/484) bolesnika na placebu, dok je povišenje (>3 x GGN) AST-a zabilježeno u 3,1% (30/958) bolesnika na tolvaptanu i 0,8% (4/484) bolesnika na placebu.
In a double-blind, placebo-controlled trial of patients with ADPKD, potentially clinically significant increased uric acid (greater than 10 mg/dL) was reported at a higher rate in tolvaptan-patients (6.2%) compared to placebo-treated patients (1.7%).
U dvostruko slijepom, placebom kontroliranom ispitivanju bolesnika s ADPBB-om moguće klinički značajan porast mokraćne kiseline (veći od 10 mg/dl) češće je zabilježen u bolesnika koji su primali tolvaptan (6,2%) u usporedbi s bolesnicima koji su primali placebo (1,7%).
In a double-blind, placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4.
U dvostruko slijepom, placebom kontroliranom, randomiziranom kliničkom ispitivanju u odraslih bolesnika s psorijatičnim artritisom, 184 bolesnika je također primilo polivalentno pneumokokno polisaharidno cjepivo u 4. tjednu.
In a double-blind, placebo-controlled, randomised clinical trial, ZOSTAVAX was administered to 100 subjects 50 years of age or older with a history of herpes zoster prior to vaccination to assess immunogenicity and safety (see section 4.8) of ZOSTAVAX.
U dvostruko slijepom, placebom kontroliranom, randomiziranom kliničkom ispitivanju, ZOSTAVAX je bio primijenjen u 100 ispitanika u dobi od 50 godina ili starijih koji su prije cijepljenja u anamnezi imali herpes zoster kako bi se procijenila imunogenost i sigurnost cjepiva ZOSTAVAX (vidjeti dio 4.8).
In a double-blind, randomised placebo- controlled study in 1,688 patients with mild or moderate hypertension, discontinuation of therapy due to a clinical adverse event occurred in 1.7% of patients treated with Rasilamlo versus 1.5% of patients given placebo.
U dvostruko slijepom, randomiziranom, placebom kontroliranom ispitivanju u kojem je sudjelovalo 1688 bolesnika s blagom do umjerenom hipertenzijom do prekida terapije zbog štetnog kliničkoga događaja došlo je u 1,7% bolesnika liječenih Rasilamlom naspram 1,5% bolesnika kojima je davan placebo.
In a double-blind, randomised, parallel-group ECG study of single, subcutaneous doses of methylnaltrexone bromide (0.15, 0.30 and 0.50 mg/kg), in 207 healthy volunteers, no signal of QT/QTc prolongation or any evidence of an effect on secondary ECG parameters or waveform morphology was detected as compared to placebo and a positive control (orally administered 400 mg moxifloxacin).
U dvostruko slijepom, randomiziranom ispitivanju s paralelnim skupinama ispitivan je EKG nakon jednokratnih supkutanih doza metilnaltreksonbromida (0,15, 0,30 i 0,50 mg/kg) kod 207 zdravih dobrovoljaca, pri čemu nisu nađeni znakovi prolongacije QT/QTc intervala niti učinci na sekundarne EKG parametre ili morfologiju kompleksa u usporedbi s placebom i pozitivnim kontrolama (peroralno davanje 400 mg moksifloksacina).
In a double-blind, randomized, active-controlled clinical study of 516 patients with invasive fungal disease caused by Aspergillus species or other filamentous fungi, elevated liver transaminases (alanine aminotransferase or aspartate aminotransferase) > 3 × Upper Limit of Normal (ULN) were reported at the end of study treatment in 4.4% of patients who received CRESEMBA.
U dvostruko-slijepom, randomiziranom, aktivnim lijekom kontroliranom kliničkom ispitivanju s 516 bolesnika s invazivnom gljivičnom bolesti uzrokovanom vrstama Aspergillus ili drugim filamentoznim gljivicama, na kraju ispitivanog liječenja zabiljeţene su povišene jetrene transaminaze (alanin aminotransferaza ili aspartat aminotransferaza) > 3 × gornje granice normale (GGN) kod 4,4 % bolesnika koji su primali lijek CRESEMBA.
In a double­blind trial comparing the efficacy and safety of liraglutide 1.8 mg versus placebo as add­ on to insulin and/or OAD in patients with type 2 diabetes and moderate renal impairment, liraglutide was superior to placebo treatment in reducing HbA1c after 26 weeks (–1.05% vs –0.38%).
U dvostruko slijepom ispitivanju koje je usporedilo djelotvornost i sigurnost 1,8 mg liraglutida u usporedbi s placebom kao dodatka terapiji inzulinom i/ili OAD u bolesnika sa šećernom bolešću tipa 2 i umjerenim oštećenjem bubrega, liraglutid je bio superioran prema liječenju placebom u smanjenju HbA1c nakon 26 tjedana (-1,05% naspram -0,38%).
In a drug interaction study, neither Intuniv nor Osmotic Release Oral System (OROS)- methylphenidate HCl extended-release were found to affect the pharmacokinetics of the other medicinal products when taken in combination.
U ispitivanju interakcije lijekova, ni Intuniv ni oralni oblik metilfenidatklorida s osmotski kontroliranim produljenim oslobađanjem nisu utjecali na farmakokinetiku drugih lijekova kad su se uzimali u kombinaciji.
In a European field trial, the incidence of clinical mastitis observed in the treated group was 9.1 % (113/1235) and in the control group 12.4 % (152/1230), showing a relative reduction in mastitis incidence of 26.0 % (p=0.0094).
U europskom terenskom ispitivanju pojava klinčkog mastitisa bila je 9,1 % (113/1235) u tretiranoj skupini, a u kontrolnoj skupini je bila 12,4 % (152/1230), što ukazuje na relativno smanjenje pojave mastitisa od 26 % (p=0,0094).
In a feasibility study evaluating a second i.p. infusion cycle consisting of 10, 20, 50 and 150 micrograms of catumaxomab in 8 patients with malignant ascites due to carcinoma (IP-CAT-AC-04)
U ispitivanju izvedivosti kojim je procjenjivan drugi ciklus i.p. infuzija koji se sastojao od 10, 20, 50 i 150 mikrograma katumaksomaba u 8 bolesnika s malignim ascitesom zbog karcinoma (IP-CAT-AC
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg-/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
U ispitivanju plodnosti i reprodukcije ženki, provedenom na štakorima, peroralne doze od 4,5 mg/kg/dan uzrokovale su malformacije (uključujući anoftalmiju, agnatiju i hidrocefalus) u prvom naraštaju potomaka, dok toksičnost za majku nije primijećena.
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
U ispitivanju plodnosti ženki i reprodukcije provedenom na štakorima, oralne doze od 4,5 mg•kg- 1•dan-1 uzrokovale su malformacije (uključujući anoftalmiju, agnatiju i hidrocefalus) u prvom naraštaju potomaka, dok toksičnost za majku nije primijećena.
In a fertility and early embryonic development study in rats, a male-mediated effect was observed at high doses (300 mcg/kg/day, s.c.) and is consistent with the sedative effects of fentanyl in animal studies.
U ispitivanju plodnosti i ranog embrionalnog razvoja provedenog u štakora, pri visokim dozama (300 mikrograma/kg na dan, s.c.) opažen je učinak posredovan mužjacima koji je u skladu sa sedativnim učincima fentanila u ispitivanjima na životinjama.
In a fertility study in male and female rats, impairment of female fertility by eslicarbazepine acetate was shown.
U ispitivanju plodnosti u mužjaka i ženki štakora, eslikarbazepinacetat je pokazao oštećenje ženske plodnosti.
In a fertility study in mice, developmental effects were observed in embryos; however, effects could also result from lower corpora lutea count and thus show impairment of fertility.
U ispitivanju plodnosti kod miševa, uočeni su razvojni učinci kod embrija, međutim, učinci mogu također rezultirati iz manjeg broja corpora lutea i na taj način pokazati poremećaje plodnosti.
In a fertility study no effects on the reproductive function of male or female Sprague-Dawley rats were observed after subcutaneous application of afamelanotide.
U ispitivanju plodnosti nisu uočeni učinci na reproduktivnu funkciju mužjaka ni ženki Sprague- Dawley štakora nakon supkutane primjene afamelanotida.
In a few animals, increased red cell destruction occurred presumably as a result of monkey anti-drug antibodies coating the red cells.
U nekoliko je životinja došlo do povećanog razaranja crvenih krvnih stanica, vjerojatno kao rezultat majmunskih antitijela na lijek koja obavijaju crvene krvne stanice.
In a few patients who use TYSABRI, over time the body’s natural defence may stop TYSABRI from working properly (the body develops antibodies to TYSABRI).
U nekoliko bolesnika koji primaju TYSABRI prirodni tjelesni obrambeni mehanizam može s vremenom zaustaviti djelovanje TYSABRIJA (tijelo stvara protutijela na TYSABRI).
In a field study conducted in dogs with chronic degenerative valvular disease 85.9% of dogs showed good compliance with treatment (≥ 90% of prescribed tablets successfully administered) over a three month period.
U terenskom ispitivanju provedenom na psima s kroničnom degenerativnom bolesti zalistaka 85,9% pasa pokazalo je dobru suradljivost (≥90% propisanih tableta uspješno je primijenjeno) tijekom razdoblja od tri mjeseca.
In a field study conducted in dogs with chronic degenerative valvular disease 85.9% of dogs showed good compliance with treatment (≥90% of prescribed tablets successfully administered) over a three month period.
U terenskom ispitivanju provedenom na psima s kroničnom degenerativnom bolesti zalistaka 85,9% pasa pokazalo je dobru suradljivost (≥90% propisanih tableta uspješno je primijenjeno) tijekom razdoblja od tri mjeseca.
In a field study to investigate the safety and efficacy of the product, hypoglycaemic events were recorded on at least one occasion in 13% (23 of 176) of treated cats.
U terenskom ispitivanju kojim se istraživala neškodljivost i djelotvornost proizvoda, hipoglikemijski događaji zabilježeni su barem jedanput u 13% (23 od 176) liječenih mačaka.
In a field trial, treated rabbits showed a lower frequency of impaction and diarrhoea than untreated rabbits (4% and 12% vs 9% and 13%, respectively).
U terenskim ispitivanjima liječeni kunići pokazali su nižu učestalost zatvora i proljeva od neliječenih kunića (4 % i 12 % naspram 9 % odnosno 13 %).
In a fixed effects meta-analysis of two Phase 3 studies, technetium Tc 99m tilmanocept localised in 99.99% of the excised lymph nodes stained blue by a vital blue dye (concordance).
U meta analizi metoda fiksnih učinaka dva ispitivanja faze 3, tilmanocept označen radioaktivnim tehnecijem Tc 99m lokaliziran je u 99,99% kirurški odstranjenih limfnih čvorova obojenih vitalnom plavom bojom (konkordancija).
In a fixed effects meta-analysis of two Phase 3 studies, technetium Tc 99m tilmanocept localised in 99.99% of the excised lymph nodes stained blue by a vital blue dye (concordance).
U meta analizi metoda fiksnih učinaka u dva ispitivanja faze 3, tilmanocept obilježen radioaktivnim tehnecijem Tc 99m lokaliziran je u 99,99% kirurški odstranjenih limfnih čvorova obojanih plavom vitalnom plavom bojom (konkordancija).
In a follicular lymphoma study involving 322 patients, patients receiving MabThera in addition to chemotherapy lived for an average of 25.9 months without the disease coming back, compared with 6.7 months in those receiving chemotherapy alone.
U ispitivanju folikularnog limfoma u koje je bilo uključeno 322 bolesnika, bolesnici koji su primali lijek MabThera uz kemoterapiju živjeli su u prosjeku 25,9 mjeseci bez povratka bolesti u usporedbi sa 6,7 mjeseci kod bolesnika koji su primali samo kemoterapiju.
In a follow-up of 162 patients five years after treatment for sBCC a mild hypopigmentation was observed in 37% of the patients and a moderate hypopigmentation was observed in 6% of the patients.
162 bolesnika pet godina nakon liječenja manjih površinskih bazeocelularnog karcinoma kože primijećena blaga hipopigmentacija u 37% bolesnika i umjerena hipopigmentacija u 6% bolesnika, dok u 56% bolesnika nije bilo promjena.
In a follow-up of the same cohort, the efficacy was confirmed up to 60 months after completion of primary vaccination without administration of a booster dose of pertussis.
Tijekom praćenja te iste kohorte potvrđena je djelotvornost do 60 mjeseci nakon završetka primarnog cijepljenja bez primjene doze docjepljivanja za pertusis.
In a follow-up study conducted in 74 children, approximately 2.5 to 3 years after the booster dose, 85.3% of the children were still seroprotected against hepatitis B and at least 95.7% were seroprotected against the three poliovirus types and PRP.
U ispitivanju praćenja provedenom u 74 djece približno 2,5 – 3 godine nakon doze docjepljivanja, u 85,3% djece i dalje je postojala seroprotekcija protiv hepatitisa B, a najmanje 95,7% njih razvilo je i seroprotekciju protiv tri tipa poliovirusa te PRP-a.
In a fourth study, the safety and efficacy of 50 mg Enbrel (two 25 mg SC injections) administered once weekly vs 25 mg Enbrel administered twice weekly were evaluated in a double-blind, placebo- controlled study of 356 patients with active ankylosing spondylitis.
U četvrtom ispitivanju ocjenjivana je sigurnost primjene i djelotvornost Enbrela 50 mg (dvije s.c. injekcije od 25 mg) primijenjenog jednom tjedno naspram 25 mg Enbrela primijenjenog dva puta tjedno u dvostruko slijepom, placebom kontroliranom ispitivanju 356 bolesnika s aktivnim ankilozantnim spondilitisom.
In a further multicentre, randomised, double-blind, active-controlled, parallel group study, a total of 1097 patients with mild to severe hypertension who were not adequately controlled on amlodipine 5 mg received Twynsta (40 mg/5 mg or 80 mg/5 mg) or amlodipine alone (5 mg or 10 mg).
U daljnjoj multicentričnoj, randomiziranoj, dvostruko-slijepoj, aktivno kontroliranoj studiji na paralenim skupinama, ukupno je 1 097 bolesnika s blagom do umjerenom hipertenzijom koji nisu bili odgovarajuće kontrolirani amlodipinom 5 mg primalo Twynstu (40 mg/5 mg ili 80 mg/5 mg) ili samo amlodipin (5 mg ili 10 mg).
In a glass beaker of suitable size place the stated amount of water containing 0.05 % w/v sodium benzoate added as a preservative.
U staklenu graduiranu čašu odgovarajuće veličine ulijte navedenu količinu vode s 0,05 % m/v natrijeva benzoata koji je dodan kao konzervans.
In a group of 2,711 plaque psoriasis patients treated with Enbrel in double- blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin cancers were reported.
U skupini od 2711 bolesnika s plak psorijazom liječenih Enbrelom u dvostruko slijepom, otvorenom ispitivanju u trajanju do 2,5 godine zabilježeno je 30 zloćudnih bolesti i 43 nemelanomska raka kože.
In a group of 2,711 plaque psoriasis patients treated with Enbrel in double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin cancers were reported.
U skupini od 2711 bolesnika s plak psorijazom liječenih Enbrelom u dvostruko slijepom otvorenom ispitivanju u trajanju do 2,5 godine zabilježeno je 30 zloćudnih bolesti i 43 nemelanomska raka kože koji nisu melanomi.
In a head-to-head comparative trial with 7-valent Prevenar, non-inferiority of the immune response to Synflorix measured by ELISA was demonstrated for all serotypes, except for 6B and 23F (upper limit of the 96.5% CI around the difference between groups >10%) (Table 6).
U izravnom (“head-to-head”) komparativnom ispitivanju sa 7-valentnim cjepivom Prevenar pokazana je neinferiornost imunološkog odgovora na Synflorix, mjereno pomoću ELISA, za sve serotipove, osim za 6B i 23F (gornja granica 96,5% CI oko razlike između skupina >10%) (Tablica6).
In a healthy subjects study, no significant change in nilotinib pharmacokinetics was observed when a single 400 mg dose of Tasigna was administered 10 hours after and 2 hours before famotidine.
U ispitivanju provedenom na zdravim ispitanicima nije opažena značajna promjena u farmakokinetici nilotiniba prilikom primjene jednokratne doze od 400 mg Tasigne 10 sati nakon i 2 sata prije primjene famotidina.
In a healthy volunteer drug interaction study of delamanid 100 mg twice daily and lopinavir/ritonavir 400/100 mg twice daily for 14 days, the exposure of the delamanid metabolite DM-6705 was 30% increased.
U ispitivanju interakcija delamanida u dozi od 100 mg dva puta na dan i lopinavira/ritonavira u dozi od 400/100 mg dva puta na dan tijekom 14 dana kod zdravih dobrovoljaca, izloženost metabolitu delamanida DM- 6705 je bila povišena za 30%.
In a healthy volunteer study, the concomitant administration of deferasirox as a moderate CYP2C8 inhibitor (30 mg/kg daily, dispersible tablet formulation), with repaglinide, a CYP2C8 substrate, given as a single dose of 0.5 mg, increased repaglinide AUC and Cmax about 2.3-fold (90% CI [2.03-2.63]) and 1.6-fold (90% CI [1.42-1.84]), respectively.
U ispitivanju na zdravim dobrovoljcima, istodobna primjena deferasiroksa kao umjerenog inhibitora CYP2C8 (30 mg/kg dnevno, formulacija tablete za oralnu suspenziju) s repaglinidom, supstratom CYP2C8, u jednokratnoj dozi od 0,5 mg, povećala je AUC repaglinida za oko 2,3 puta (90% CI [2,03 2,63]) i Cmax repaglinida za 1,6 puta (90% CI [1,42 1,84]).
In a Japanese Phase I study that utilized 5 dose groups with doses ranging from 25 to 200 mg/body, there was a dose-proportional increase in exposure for tegafur, gimeracil and oteracil.
U japanskoj studiji faze I koja je koristila 5 doznih skupina s rasponima doza od 25 do 200 mg/organizmu, uočen je dozi proporcionalni porast izloženosti tegafuru, gimeracilu i oteracilu.
In a juvenile toxicity study in dogs treated from post natal day 14 to day 42, a decreased testicular weight and Leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and oedema of vaginal tissues were seen in females from 4 mg/kg/day.
U ispitivanju toksičnosti na mladunčadi pasa liječene od 14. do do 42. postnatalnog dana opažena je smanjena težina testisa i veličine Leydigovih stanica u mužjaka kod doze od 6 mg/kg na dan i povećana težina uterusa, hipertrofija uterusa i cerviksa te edem vaginalnog tkiva u ženki kod doza od 4 mg/kg na dan.
In a juvenile toxicity study in rats treated from post natal day 10 to day 63 aprepitant led to an earlier vaginal opening in females from 250 mg/kg b.i.d. and to a delayed preputial separation in males, from 10 mg/kg b.i.d.
U ispitivanju toksičnosti na mladunčadi štakora, liječenje aprepitantom od 10. do 63. postnatalnog dana dovelo je do ranijeg otvaranja vagine u ženki kod doza od 250 mg/kg dvaput na dan i do kasnijeg razdvajanja prepucija u mužjaka kod doza od 10 mg/kg dvaput na dan.
In a juvenile toxicity study in rats treated from post natal day 10 to day 63 aprepitant led to an earlier vaginal opening in females from 250 mg/kg b.i.d. and to a delayed preputial separation in males, from 10 mg/kg b.i.d.
U ispitivanju toksičnosti na mladunčadi štakora, liječenje aprepitantom od 10. do 63. postnatalnog dana dovelo je do ranijeg otvaranja vagine u ženki kod doza od 250 mg/kg dvaput na dan i do kasnijeg razdvajanja prepucija u mužjaka kod doza od od 10 mg/kg dvaput na dan.
In a juvenile toxicity study in which sexually immature rats were treated daily with 3 mg/kg for 7 weeks, atrophy of testes and epididymides were observed.
U ispitivanjima toksičnosti kod mladunaca u kojima su spolno nezreli štakori dnevno primali 3 mg/kg u razdoblju od 7 tjedana, primijećena je atrofija sjemenika i pasjemenika.
In a laboratory study, the development of papillomas was noted in a number of dogs.
U laboratorijskom ispitivanju je razvoj papiloma uočen kod nekih pasa kojima je dana preporučena doza.
In a large (N=1050) major orthopedic/general surgery trial, patients received an initial dose of parecoxib 40 mg IV, then 20 mg IV Q12H for a minimum of 3 days followed by valdecoxib PO (20 mg Q12H) (n=525) for the remainder of a 10 day treatment period, or placebo IV followed by placebo PO (n=525).
U velikom (N=1050) glavnom ispitivanju kod ortopedskih/općekirurških operacija, bolesnici su primili početnu dozu parekoksiba od 40 mg i.v., a potom 20 mg i.v. svakih 12 sati tijekom najmanje 3 dana nakon čega je slijedilo davanje valdekoksiba oralno (20 mg svakih 12 sati) (n=525) tijekom preostalih 10 dana liječenja ili placeba i.v. pa potom placeba oralno (n=525).
In a large multicentre, double-blind study, they examined 3,171 patients admitted in the acute phase of unstable angina or non-Q-wave myocardial infarction.
U velikom multicentričnom, dvostruko slijepom ispitivanju ispitan je 3171 bolesnik primljen u akutnoj fazi nestabilne angine pektoris ili infarkta miokarda bez Q zupca.
In a large multicentre, double-blind study, they examined 3,171 patients admitted in the acute phase of unstable angina or non-Q-wave myocardial infarction.
U velikom multicentričnom, dvostruko slijepom ispitivanju ispitan je 3171 bolesnik primljen u akutnoj fazi nestabilne angine pektoris ili infarkta miokarda bez Q-zupca.